SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242417141 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Panagiota Bouti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, The Nethe…. Hauptthemen laut MEDLINE: Neutrophils, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society.
Abstract (Originalsprache)
Since the successful introduction of checkpoint inhibitors targeting the adaptive immune system, monoclonal antibodies inhibiting CD47-SIRPα interaction have shown promise in enhancing anti-tumor treatment efficacy. Apart from SIRPα, neutrophils express a broad repertoire of inhibitory receptors, including several members of the sialic acid-binding receptor (SIGLEC) family. Here, we demonstrate that interaction between tumor cell-expressed sialic acids and SIGLEC-5/14 on neutrophils inhibits antibody-dependent cellular cytotoxicity (ADCC). We observed that conjugate formation and trogocytosis, both essential processes for neutrophil ADCC, were limited by the sialic acid-SIGLEC-5/14 interaction. During neutrophil-tumor cell conjugate formation, we found that inhibition of the interaction between tumor-expressed sialic acids and SIGLEC-5/14 on neutrophils increased the CD11b/CD18 high affinity conformation. By dynamic acoustic force measurement, the binding between tumor cells and neutrophils was assessed. The interaction between SIGLEC-5/14 and the sialic acids was shown to inhibit the CD11b/CD18-regulated binding between neutrophils and antibody-opsonized tumor cells. Moreover, the interaction between sialic acids and SIGLEC-5/14-consequently hindered trogocytosis and tumor cell killing. In summary, our results provide evidence that the sialic acid-SIGLEC-5/14 interaction is an additional target for innate checkpoint blockade in the tumor microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, 1066 CX Amsterdam, The Netherlands.
- LUMICKS, Paalbergweg 3, 1105 AG Amsterdam, The Netherlands.
- Department of Pediatric Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
ORCID-Profile: Reza Nadafi, Rogier M Reijmers
Förderung
- Dutch Cancer Society
Zitieren
APA
Bouti, P., Blans, C., Klein, B. J. A. M., Shome, D., Nadafi, R., Van Houdt, M., Schornagel, K., Verkuijlen, P. J. J. H., Roos, V., Reijmers, R. M., Van Bruggen, R., Kuijpers, T. W., & Matlung, H. L. (2023). SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417141
Vancouver
Bouti P, Blans C, Klein BJAM, Shome D, Nadafi R, Van Houdt M, et al. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417141
BibTeX
@article{Bouti2023,
author = {Bouti, Panagiota and Blans, Colin and Klein, Bart J A M and Shome, Debarati and Nadafi, Reza and Van Houdt, Michel and Schornagel, Karin and Verkuijlen, Paul J J H and Roos, Virginie and Reijmers, Rogier M and Van Bruggen, Robin and Kuijpers, Taco W and Matlung, Hanke L},
title = {SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242417141}
}
EUVIMED